Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4249 trials
Conditions Advanced Breast Cancer
Phase PHASE1
Enrollment 58
Locations 4 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-30
Study Details Design, interventions, and primary outcomes

About This Study

DM5167 is a second-generation of PARP inhibitor that selectively targets the PARP-1 enzyme. This results in less haematological toxicity and a high level of safety. The aim of the study is to assess the safety and tolerability of DM5167 in patients with advanced solid tumors not respond to other treatments.

Design

Study type: Interventional Phases: Phase1 Allocation: Non Randomized Intervention model: Sequential Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: DM5167 — Once daily for 28 days

Primary Outcomes

  • Part 1: Incidence of dose limiting toxicities (DLT) of DM5167 (During the first cycle (28 days) of DM5167 treatment)
  • Part 1 and Part 2: Treatment emergent adverse events (TEAE) and serious adverse events (SAEs) (First dose up to 28 days post end of treatment)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2024-10-24
Completion: 2027-01-31
Eligibility
Age: 19 Years and older
Sex: ALL
Volunteers: false
Enrollment: 58 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: DIGMBIO
Contact Information
Study Contact:
MyungEun Jung
+82 31 757 220
myungeun@digmbio.com
Jee-Hyun Kim
jhkimmd@snu.ac.kr
Seoul National University Bundang Hospital
Jee-Hyun Kim
Seoul National University Bundang Hospital
Interventions
  • Drug: DM5167 — Once daily for 28 days
Study Locations (4 sites)
Seoul National University Bundang Hospital, Gyeonggi-do, South Korea
Samsung Medical Center, Seoul, South Korea
Seoul National University Hospital, Seoul, South Korea
Severance Hospital, Seoul, South Korea
Eligibility Criteria
Inclusion Criteria: * Men and women aged 19 years or older as of the date of written informed consent * Patients who have at least one measurable lesion according to RECIST version 1.1 * ECOG performance status ≤ 1 * Patients with life expectancy ≥ 12 weeks * Patients who meet the clinical laboratory test criteria confirming adequate liver, renal, and hematologic function * Patients who voluntarily provide written informed consent to participate in this study * Patients with histologically or cytologically confirmed unresectable advanced solid tumors * Patients who have BRCA1/BRCA2 mutations Exclusion Criteria: * Patients with a medical history of significant illness * Patients with QT interval of \> 450 ms (for men) or \> 460 ms (for women)\\ * Patients who have not yet recovered from toxicity related to previous anticancer therapy * Patients were predicted to demonstrate hypersensitivity to the components of the investigational medicinal product * Patients who have participated in another clinical trial and received an investigational product or medical device * Other individuals deemed inappropriate for participation in the study by the investigator
Conditions Locally Advanced Breast Cancer, Unresect...
Phase PHASE1, PHASE2
Enrollment 380
Locations 79 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-30
Study Details Design, interventions, and primary outcomes

About This Study

This is a Phase I/II, multi-site, open-label, two-part study designed to evaluate the efficacy, safety, optimized dose and contribution of components of BNT323 (also known as trastuzumab pamirtecan and DB-1303) in combination with BNT327 (also known as pumitamig and PM8002) in participants with hormone receptor-positive (HR+) or hormone receptor-negative (HR-), Human epidermal growth factor receptor (HER)2-positive, HER2-low (immunohistochemistry \[IHC\] 1+ or IHC 2+/in situ hybridization -), HER2-ultralow (IHC 0, with membrane staining) or HER2-null breast cancer (BC), or triple-negative breast cancer (TNBC).

Design

Study type: Interventional Phases: Phase1, Phase2 Allocation: Randomized Intervention model: Sequential Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: BNT323 — Intravenous infusion
  • Drug: BNT327 — Intravenous infusion

Primary Outcomes

  • Part 1 - Occurrence of dose limiting toxicities (DLTs) (During the DLT evaluation period (Cycle 1), i.e., the time of initiation of the first dose of investigational medicinal product (IMP) up to 21 days)
  • Occurrence of Treatment-emergent adverse events (TEAEs), Grade ≥3 TEAEs, serious adverse events (SAEs), treatment-related TEAEs, treatment-related Grade ≥3 TEAEs, and treatment-related SAEs (From the time of initiation of the first dose of IMP to 90 days after the last IMP dose)
  • Occurrence of dose interruption, reduction, and discontinuation due to TEAEs (From the time of initiation of the first dose of IMP to 90 days after the last IMP dose)
  • Part 2 - Objective response rate (ORR) (From the time of initiation of the first dose of IMP to last tumor assessment scan, i.e., up to 36 months.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1, PHASE2
Status: Recruiting
Start Date: 2025-04-23
Completion: 2029-08
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 380 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: BioNTech SE
Collaborators: DualityBio Inc., BioNTech (Shanghai) Pharmaceuticals Co., Ltd.
Principal Investigators:
  • BioNTech Responsible Person (STUDY_DIRECTOR) - BioNTech SE
Contact Information
Study Contact:
BioNTech clinical trials patient information
+49 6131 9084
patients@biontech.de
Interventions
  • Drug: BNT323 — Intravenous infusion
  • Drug: BNT327 — Intravenous infusion
Study Locations (79 sites)
Beverly Hills Cancer Center, Beverly Hills, California 90211 United States
Hoag Memorial Hospital Presbyterian, Newport Beach, California 92663 United States
Hematology - Oncology Associates of the Treasure Coast, Port Saint Lucie, Florida 34952 United States
University Cancer & Blood Center, LLC, Athens, Georgia 30607 United States
Winship Cancer Institute of Emory University, Atlanta, Georgia 30322 United States
University of Illinois Hospital & Health Sciences System, Chicago, Illinois 60612 United States
Karmanos Cancer Institute, Detroit, Michigan 48201 United States
Brigitte Harris Cancer Pavilion BHCP, Detroit, Michigan 48202 United States
START Midwest, LLC, Grand Rapids, Michigan 49546 United States
Saint Luke's Hospital of Kansas City, Kansas City, Missouri 64111 United States
Eligibility Criteria
Key Inclusion Criteria (applicable to all participants and all parts unless otherwise specified): * Have pathologically documented BC that: * Is locally advanced, unresectable or metastatic. * Has a confirmed HER2 status as determined by the local laboratory as standard of care testing prior to study screening (Part 1, Part 2 Cohorts 2 and 4) or the central laboratory (Part 2, Cohorts 1 and 3) from the most recently collected pre-randomization tumor sample. * Has a documented history of HER2 expression consistent with the subgroup definitions (i.e., HER2-low, HER2-ultralow, HER2-null, HER2-positive, or TNBC) as per current American Society of Clinical Oncology/College of American Pathologists guidelines. * Have measurable disease defined by RECIST v1.1. * Has left ventricular ejection fraction ≥55% by either echocardiography or multi-gated acquisition (scanning) within 28 days before randomization/enrollment. Key Exclusion Criteria: * Have history of small bowel obstruction requiring hospitalization within the past 3 months prior to the first dose of IMP. * Have an uncontrolled intercurrent illness that would limit compliance with study requirement or substantially increase risk of incurring adverse events. * Have clinically uncontrolled pleural effusion, ascites or pericardial effusion requiring drainage, peritoneal shunt, or cell-free concentrated ascites reinfusion therapy within 2 weeks prior to randomization/enrollment. * Have a history of (non-infectious) interstitial lung disease (ILD)/pneumonitis that required steroids, have current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening. * Had prior treatment with topoisomerase I inhibitors, including antibody-drug conjugates with topoisomerase I inhibitor payloads such as trastuzumab deruxtecan. * Have received any of the following therapies or drugs prior to the initiation of the study: * Participants who have received prior treatment with BNT323. * Participants who received prior treatment with a programmed death-ligand 1 (PD-L1) / vascular endothelial growth factor (VEGF) bispecific antibody. Note: Prior treatment with programmed death 1 (PD-1)/VEGF bispecific antibodies, PD-1/PD-L1 inhibitors or anti-VEGF therapies are permitted. * Have received other systemic immunostimulatory agents or immunosuppressive therapies (such as interferon-α, interleukin-2, or methotrexate) within 4 weeks prior to the initiation of study treatment or are within five half-lives of the treatment drug (whichever is longer). Exception: excluding local, intranasal, intraocular, intra-articular or inhaled corticosteroids, short term use (≤7 days) of corticosteroids for prophylaxis (e.g., prevention of contrast agent allergy) or treatment of non-autoimmune conditions (e.g., delayed hypersensitivity reactions caused by exposure to allergens). * Have received systemic corticosteroids (at a dosage greater than 10 mg/day of prednisone or an equivalent dose of other corticosteroids) within 3 weeks prior to the initiation of study treatment. NOTE: Other protocol defined Inclusion/Exclusion criteria apply.
Conditions Breast Cancer
Phase NA
Enrollment 100
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-30
Study Details Design, interventions, and primary outcomes

About This Study

For patients with early breast cancer with negative axillary lymph nodes, sentinel lymph node biopsy (SLNB) can largely avoid complications such as upper limb lymphoedema caused by axillary lymph node dissection (ALND). Locally advanced breast cancer requires neoadjuvant chemotherapy (NAC), based on the breast cancer treatment guidelines. In addition to shrinking the primary breast lesion, NAC can reduce the stage for axillary positive lymph nodes. Therefore, in recent years clinicians have been considering SLNB for patients whose axillary lymph nodes have turned negative after NAC. After verification by the clinical trials, the current NCCN guidelines recommend that patients with T1-3N0-1 undergo SLNB after NAC, however, the false negative rate (FNR) of conventional SLNB after NAC is as high as 14%, which potentially leads to underestimation of the risk for recurrence and metastasis, insufficient adjuvant therapy, eventually affects long-term survival. Thus, how to accurately assess and treat axillary lymph nodes after NAC remains an urgent clinical question to be answered. In recent years, a method using a metal clip to label positive lymph node before NAC has emerged in order to reduce the FNR of SLNB after NAC. Its principle is to trace the metastasized lymph node, so that the lymph node can be accurately found in the surgery, even if the lymph node is not blue-stained at the time. Apparently, this method is more suitable for small number of nodes, and inappropriate for more than two metastasized nodes. The diameter of manocarbon particles (150nm) is between that of lymphatic capillaries (120-500nm) and capillaries (20-50 nm). With the unique macrophage phagocytosis, nanocarbon particles can remain in the lymphatic system for a long time. Using nanocarbon to label positive lymph nodes before NAC, our pilot study explored the regression of axillary lymph nodes after NAC. We found that, except for a small number of drug-resistant patients, the regression of positive lymph nodes after NAC followed a pattern of from the superior to the inferior, and from the medial to the lateral. We also found that, the worse the efficacy of NAC, the fewer black-stained nodes after NAC, suggesting long-term tracing of positive axillary lymph nodes by nanocarbon particles can guide precise treatment of axillary lymph nodes after NAC. These findings are integrated with our previous research project which investigated the spatial distribution of positive axillary lymph nodes with the intercostals brachial nerve (ICBN) as the boundary. It is proposed that low lymph node dissection below ICBN (pALND) may be a safe and efficient method reducing lymphoedema in patients with negative nodes after NAC. Prone position CT scan combined with clinical palpation of axillary lymph nodes can comprehensively evaluate axillary conditions in patients with breast cancer before surgery, and determine node metastasis accurately, and make correct clinical plans.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Procedure: SLNB — undergo fluorescence SLNB.
  • Procedure: pALND — undergo low axillary lymph node dissection with ICBN as the boundary
  • Procedure: ALND — undergo ALND

Primary Outcomes

  • post-surgery pathology concordance rate (up to 3 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2021-11-01
Completion: 2028-10-31
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Shengjing Hospital
Principal Investigators:
  • Jianyi Jianyi, Master (PRINCIPAL_INVESTIGATOR) - Cancer Hospital of China Medical University, Liaoning Cancer Hospital
Contact Information
Study Contact:
Jianyi Li, Master
8618940257177
sjbreast@yeah.net
Jianyi Li, Dr.
13390127607
sjbreast@yeah.net
Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute
Jianyi Li, Master
86-18940257177
sjbreast@yeah.net
Jianyi Li
Interventions
  • Procedure: SLNB — undergo fluorescence SLNB.
  • Procedure: pALND — undergo low axillary lymph node dissection with ICBN as the boundary
  • Procedure: ALND — undergo ALND
Study Locations (2 sites)
Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, Shenyang, Liaoning 110042 China
Jianyi Li, Shenyang, Liaoning 110042 China
Eligibility Criteria
Inclusion Criteria: * invasive breast cancer confirmed by biopsy and histology; * based on prone CT scan and Doppler ultrasound, axillary stage cN2-3; * agree and meet the requirements for NAC; * meet surgical requirements and agree to undergo surgery after NAC; * the regime of NAC follows the NCCN recommendations. Exclusion Criteria: • previous history of breast cancer or other malignant tumors.
Conditions Lung Cancer, Breast Cancer, Gastric Canc...
Phase Not Applicable
Enrollment 55
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-30
Study Details Design, interventions, and primary outcomes

About This Study

To explore the consistency between result of PTC drug screening tests and actual clinical outcome for patients with advanced malignancy.

Design

Study type: Observational Observational model: Case Only Time perspective: Prospective

Interventions / Regimen

  • Diagnostic Test: Patient-derived tumor-like cell clusters (PTC) drug sensitivity testing. — Fresh malignant effusion samples were collected from advanced malignancy patients for PTC drug sensitivity testing, then assess the accuracy of this diagnostic test by combination and analysis with final clinical outcome.

Primary Outcomes

  • Complete Response (CR) (up to 12 months)
  • Partial Response (PR) (up to 12 months)
  • Progressive Disease (PD) (up to 12 months)
  • Stable Disease (SD) (up to 12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2023-08-04
Completion: 2025-12
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 55 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Liu Huang
Collaborators: Beijing GeneX MedLab Co., Ltd
Principal Investigators:
  • Liu Huang (PRINCIPAL_INVESTIGATOR) - Tongji Hospital
Contact Information
Study Contact:
Liu Huang
63639656
huangliu@tjh.tjmu.edu.cn
Liu Huang
63639656
huangliu@tjh.tjmu.edu.cn
Tongji Hospital
Interventions
  • Diagnostic Test: Patient-derived tumor-like cell clusters (PTC) drug sensitivity testing. — Fresh malignant effusion samples were collected from advanced malignancy patients for PTC drug sensitivity testing, then assess the accuracy of this diagnostic test by combination and analysis with final clinical outcome.
Study Locations (1 sites)
Tongji Hospital, Wuhan, Hubei 430030 China
Eligibility Criteria
Inclusion Criteria: 1. 18 to 75 years old, regardless of gender. 2. Score of nutrition risk screening 2002 (NRS2002) is less than 3, NRS20023. 3. Advanced and unresectable malignancy confirmed by biopsy diagnosis. 4. Able to tolerate anti-tumor treatment, and without serious cardiopulmonary and other underlying diseases. 5. Score of eastern cooperative oncology group (ECOG) is not higher than 2, ECOG≤2. 6. Anticipated survival exceed six months. 7. At least one measurable lesions (according to RECIST 1.1) 8. Resistance or intolerance to standard therapy regimens. 9. Signed informed consent form voluntarily. Exclusion Criteria: 1. Pregnant or lactating women. 2. Have Participated other clinical trials in six months. 3. Severe liver dysfunction. 4. Severe renal dysfunction. 5. Patients with cognitive disorder, mental diseases and terrible compliance. 6. Allergic to known chemotherapeutic agents. 7. Other circumstance not suitable to participate in this trial determined by investigators.
Conditions Cancer Risk, Breast Cancer Risk
Phase NA
Enrollment 400
Locations 4 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-30
Study Details Design, interventions, and primary outcomes

About This Study

This is a multi-center, single arm trial to evaluate the cancer detection rate of supplemental screening magnetic resonance imaging (MRI) in participants who are high-risk by Mirai-MRI assessment. Mirai is an accurate cancer risk model based on full-resolution mammograms.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Screening Masking/blinding: None

Interventions / Regimen

  • Procedure: Magnetic resonance imaging (MRI) — Undergo Magnetic resonance (MR) imaging
  • Device: Artificial Intelligence (AI) — AI applied to MRI images

Primary Outcomes

  • Cancer detection rate (CDR) (Up to 1 year)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-11-03
Completion: 2027-01-31
Eligibility
Age: 40 Years and older
Sex: FEMALE
Volunteers: true
Enrollment: 400 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of California, San Francisco
Collaborators: Breast Cancer Research Foundation
Principal Investigators:
  • Maggie Chung, MD (PRINCIPAL_INVESTIGATOR) - University of California, San Francisco
Contact Information
Study Contact:
Tiffany Tran
877-827-3222
tiffany.tran3@ucsf.edu
Tiffany Tran
tiffany.tran3@ucsf.edu
University of California, San Francisco
cancertrials@ucsf.edu
University of California, San Francisco
Interventions
  • Procedure: Magnetic resonance imaging (MRI) — Undergo Magnetic resonance (MR) imaging
  • Device: Artificial Intelligence (AI) — AI applied to MRI images
Study Locations (4 sites)
University of California, San Diego, San Diego, California 92093 United States
University of California, San Francisco, San Francisco, California 94143 United States
University of Chicago Comprehensive Cancer Center, Chicago, Illinois 60637 United States
University of Massachusetts Memorial Medical Center, Worcester, Massachusetts 01655 United States
Eligibility Criteria
Inclusion Criteria: 1. All asymptomatic participants assigned female at birth, ages 40-89 years old with screening mammography assessed as Breast Imaging Reporting and Data System (BI-RADS) 1, BI-RADS 2, or initial BI-RADS 0 with subsequent diagnostic mammogram assessed as BI-RADS 1 or BI-RADS 2. 2. Screening mammogram assessed as high-risk by Mirai (top 3 percentile of 2-year risk). 3. Availability of a routine screening mammogram report, along with a subsequent diagnostic mammogram report if applicable, and access to the corresponding Digital Imaging and Communications in Medicine (DICOM) images. 4. Ability to understand and the willingness to sign a written informed consent document. Exclusion Criteria: 1. Screening mammogram that is assessed as BI-RADS 0 for technical recall. 2. Contraindications for MRI: 1. Metallic foreign body in the eye. 2. MRI unsafe implants and/or medical devices. 3. Adverse reaction to a (gadolinium-based) contrast agent in the past. 4. Pregnant women. 5. Claustrophobia. 6. Exceeds site specific size and/or weight limit for MRI. 3. If the participant meets site-specific criteria for screening estimated glomerular filtration rate (eGFR) prior to MRI, participants with severely impaired renal function (GFR \< 30 mL/min) will be excluded. According to University of California, San Francisco's policy for MRI with contrast (gadolinium-containing), serum creatinine with calculation of eGFR should be obtained within 6 weeks of the MRI study for participants with any of the following risk factors: 1. History of "kidney disease" as an adult, including renal tumor or transplant. 2. Diabetes treated with insulin or other prescribed medications. 3. Hypertension (high blood pressure) requiring medication. 4. Multiple myeloma. 5. Solid organ transplant. 6. History of severe hepatic disease/liver transplant/pending liver transplant.
Conditions Lymphedema, Edema
Phase NA
Enrollment 60
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-30
Study Details Design, interventions, and primary outcomes

About This Study

To investigate whether the addition of Fibralign's BioBridge® Collagen Matrix (BioBridge) devices to the standard surgery for vascularized lymph node transfer will improve the outcome of surgical treatment in lymphedema of the upper arm.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Device: BioBridge® Collagen Matrix — BioBridge Collagen Matrix (BioBridge) is a sterile implantable bio-compatible and biodegradable surgical mesh ribbon comprised of highly purified porcine collagen. The Class II device was cleared by CDRH Division of Surgical Devices on 8 January 2016 under 510(k) K151083. The device will be used for soft tissue surgical support at the time of vascularized lymph node transplant surgery (VLNT); the device will be used, specifically, for surgical support of the lymphatic component of the soft tissue.
  • Procedure: Vascularized Lymph Node Transfer (VLNT) — Micro-surgical procedure for vascularized lymph node transfer (VLNT)

Primary Outcomes

  • Excess limb volume change (Baseline and 12 months after treatment)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2020-10-26
Completion: 2025-12-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Fibralign Corporation
Collaborators: University of Chicago
Principal Investigators:
  • David W Chang, MD, FACS (PRINCIPAL_INVESTIGATOR) - The University of Chicago Medicine & Biological Sciences
  • Rebecca Garza, MD (STUDY_DIRECTOR) - The University of Chicago Medicine & Biological Sciences
Contact Information
Study Contact:
Scully Hsu
773-834-8038
shsu@bsd.uchicago.edu
Janine Grohar
773-702-0316
jgrohar@bsd.uchicago.edu
The University of Chicago Biological Sciences Division/University of Chicago Medical Center
Edward I Chang, MD
MD Anderson
Interventions
  • Device: BioBridge® Collagen Matrix — BioBridge Collagen Matrix (BioBridge) is a sterile implantable bio-compatible and biodegradable surgical mesh ribbon comprised of highly purified porcine collagen. The Class II device was cleared by CDRH Division of Surgical Devices on 8 January 2016 under 510(k) K151083. The device will be used for soft tissue surgical support at the time of vascularized lymph node transplant surgery (VLNT); the device will be used, specifically, for surgical support of the lymphatic component of the soft tissue.
  • Procedure: Vascularized Lymph Node Transfer (VLNT) — Micro-surgical procedure for vascularized lymph node transfer (VLNT)
Study Locations (2 sites)
The University of Chicago Biological Sciences Division/University of Chicago Medical Center, Chicago, Illinois 60637 United States
MD Anderson, Houston, Texas 77030 United States
Eligibility Criteria
Inclusion Criteria: The subject must be a breast cancer survivor, at least 3 years beyond completion of cancer therapy, free of clinical disease, and eligible for surgical intervention. Participants who are not able to safely undergo general anesthesia and/or perioperative care for VLNT are excluded. * Ages 18 to 75 years (inclusive) * Eastern Cooperative Oncology Group (ECOG) Performance Status 0 to 2 * Life expectancy \> 2 years * Acquired (secondary) upper limb lymphedema secondary to breast cancer treatment * The participant must be eligible for surgical intervention * Swelling of 1 limb that is not completely reversed by elevation or compression * Stage I-II lymphedema at screening, based on the International Society of Lymphology (ISL) staging system * Participants must have no evidence of disease (NED), have completed breast cancer therapy 3 years prior to enrollment; use of endocrine therapy is allowed. * Completion of a full course of complete decongestive therapy (CDT), according to ISL guidelines at least 12 weeks prior to screening, including use of compression garments for at least 12 weeks without change in regimen * Willingness to comply with recommended regimen of self care, with consistent use of compression garments from screening through the entire study duration (through the safety follow up visit), excluding the first 3 weeks postoperatively where patients are required to not wear compression. Self bandaging, use of nighttime compression garments, and intermittent pneumatic compression devices are allowed, but the procedures and regimens are expected to remain consistent from screening though the entire study duration. * Consistent use of an appropriately sized compression garment for daytime use. * Limb volume (LV) in the affected limb and unaffected limb must be at least 10% of each other. * Evidence of abnormal bioimpedance ratio, if feasible, based upon unilateral disease: L Dex \> 10 units. * Willingness and ability to comply with all study procedures, including measurement of skin biopsy, and preoperative and postoperative imaging studies. * Willingness and ability to understand, and to sign a written informed consent form document Exclusion Criteria: * Edema arising from increased capillary filtration will be excluded (venous incompetence). * Inability to safely undergo general anesthesia and/or perioperative care related to vascularized lymph node transfer * Concurrent participation in a clinical trial of any other investigational drug or therapy, regardless of indication, within 1 month before screening or 5 times the drug's half life, whichever is longer * Recent initiation (≤ 12 weeks) of CDPT for lymphedema * Other medical condition that could lead to acute limb edema, such as (but not limited to) acute venous thrombosis or heart failure * Other medical condition that could result in symptoms overlapping those of lymphedema in the affected limb (eg, pain, swelling, decreased range of motion) * History of clotting disorder (hypercoagulable state) * Chronic (persistent) infection in the affected limb * Infection of the lymphedema limb within 1 month prior to screening * Currently receiving chemotherapy or radiation therapy * Current evidence, or a history of malignancy within the past 3 years (except for non melanoma skin cancer or cervical cancer in situ treated with curative intent). If the participant has undergone cancer treatment, this must have been completed \> 3 years prior to enrollment. * Significant or chronic renal insufficiency (defined as serum creatinine \> 2.5 mg/dL or an estimated glomerular filtration rate \[eGFR\] \< 30 mL/min at screening) or requires dialytic support * Hepatic dysfunction, defined as alanine transaminase (ALT) or aspartate transaminase (AST) levels \> 3 × upper limit of the normal range (ULN) and/or bilirubin level \> 2 × ULN at screening * Absolute neutrophil count \< 1500 mm3 at screening * Hemoglobin concentration \< 9 g/dL at screening * Body Mass Index (BMI) \>35 * Known sensitivity to porcine products * Anaphylaxis to iodine * Pregnancy or nursing * Substance abuse (such as alcohol or drug abuse) within 6 months prior to screening * Any reason (in addition to those listed above) that, in the opinion of the investigator, precludes full participation in the study.
Conditions Breast Cancer, Breast Neoplasms, Breast ...
Phase PHASE2
Enrollment 20
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-30
Study Details Design, interventions, and primary outcomes

About This Study

The extent of breast cancer is an important prognostic factor in patients diagnosed with this disease. Therefore, adequate staging at diagnosis is a requisite for optimal treatment. In all patients diagnosed with locally advanced breast cancer (LABC), distant staging using 18F-FDG PET/CT is recommended. However, the degree of metabolic uptake in the primary breast tumor is significantly lower in the ER+ subtype compared to HER2+ and triple negative breast cancer (TNBC). As a consequence, a suboptimal 18F-FDG uptake in ER+ breast cancer patients can potentially lead to missed distant metastases. Fibroblast-activating protein inhibitor (FAPI) is a recently developed radiotracer that binds to FAP, a stromal antigen overexpressed in more than 90% of epithelial-derived tumors and their metastases. Previous studies all show 68Ga-FAPI PET/CT to have a higher detection rate compared to 18F-FDG PET/CT. However, all previous studies were performed without considering breast cancer subtype. If the metabolic uptake by 68Ga-FAPI-46 is higher in ER+ breast cancer patients, more lesions will be detected, resulting in a more appropriate treatment for these patients. Therefore, in this pilot study, the investigators aim to compare the diagnostic performance of 18F-FDG with 68Ga-FAPI-46 as PET-tracer in ER+ breast cancer patients.

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Diagnostic Masking/blinding: None

Interventions / Regimen

  • Diagnostic Test: 68Ga-FAPI-46 PET/CT and 68Ga-FAPI-46 PET/MRI — All participating patients will undergo an additional 68Ga-FAPI- 46 PET/CT and 68Ga-FAPI-46 PET/MRI scan prior to their breast cancer treatment.

Primary Outcomes

  • To determine essential input parameters for an adequate sample size calculation for a diagnostic study that compares the diagnostic accuracy of 18F-FDG and 68Ga-FAPI-46 as PET tracer in patients with ER+ breast cancer. (Patients will be followed from diagnosis until the additional imaging exams are performed, within 20 working days both PET exams will be performed.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-09-01
Completion: 2027-03
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 20 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Maastricht University Medical Center
Contact Information
Study Contact:
Thiemo JA van Nijnatten, MD, PhD
+31433876910
thiemo.nijnatten@mumc.nl
Lisa EHW Duijx, MSc
+31639289798
lisa.duijx@mumc.nl
Thiemo JA van Nijnatten, MD, PhD
thiemo.nijnatten@mumc.nl
Maastricht University Medical Center+
Interventions
  • Diagnostic Test: 68Ga-FAPI-46 PET/CT and 68Ga-FAPI-46 PET/MRI — All participating patients will undergo an additional 68Ga-FAPI- 46 PET/CT and 68Ga-FAPI-46 PET/MRI scan prior to their breast cancer treatment.
Study Locations (1 sites)
Maastricht University Medical Center+, Maastricht, 5800 Netherlands
Eligibility Criteria
Inclusion Criteria: * Female patient with histopathologically proven ER+ breast cancer. * Diagnosed with locally advanced (primary tumor \>5 cm and/or presence of axillary lymph node metastases) or recurrent breast cancer, or metastatic breast cancer for which 18F-FDG PET/CT or 18F-FDG PET/MRI staging is performed. * Willing and able to undergo the study procedures. * Has personally provided written informed consent. Exclusion Criteria: * Age \<18 * Pregnancy * Patients with secondary malignancies (except non-melanoma skin cancer) * No 18F-FDG PET/CT or 18F-FDG PET/MRI scan. * Contra-indications for PET/MRI such as pacemaker, aneurysm clips, metallic device in their body, severe claustrophobia, and severe obesity * Chronic inflammatory disease such as rheumatoid arthritis. * Patients with severe hepatic or renal impairment (eGFR ≤45mL/min/1.73m²) * Inability to provide informed consent.
Conditions Breast Neoplasm Female
Phase NA
Enrollment 154
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-30
Study Details Design, interventions, and primary outcomes

About This Study

This study is a prospective, open, multi-center, single arm trial. The treatment group will receive six cycles of docetaxel, carboplatin combined with Inetetamab and Pyrotinib before surgery. By focusing on tpCR (ypT0/is, ypN0) evaluated by pathology, the efficacy of docetaxel, carboplatin combined with Inetetamab and Pyrotinib in the preoperative treatment of locally advanced HER2-positive breast cancer will be evaluated. During long-term follow-up, event-free survival (EFS), disease-free survival (DFS), distant metastasis-free survival (DDFS), overall survival (OS), central nervous system disease-free survival (CNSDFS) under this treatment regimen will be evaluated, and the efficacy-related biomarkers will be explored. The cardiotoxicity of Inetetamab and Pyrotinib in the treatment of breast cancer is also be evaluated.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Docetaxel — 75mg/m2 iv escalating to 100mg/m2 iv 3-weekly
  • Drug: Carboplatin — AUC=6 min/mL iv 3-weekly
  • Drug: Inetetamab — 8mg/kg iv loading dose, followed by 6mg/kg iv 3-weekly
  • Drug: Pyrotinib — 400mg orally daily

Primary Outcomes

  • tpCR (Approximately 5 months from randomization following surgery or early withdrawal, whichever occurred first (Surgery was performed within 2 weeks after Cycle 6))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2021-11-27
Completion: 2031-08-01
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 154 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Wang Ouchen
Contact Information
Study Contact:
Wang OC Ouchen, Doctor
13957706099
woc099@163.com
the First Affiliated Hospital of Wenzhou Medical University
Wu WZ Weizhu, Doctor
the First Affiliated Hospital of Wenzhou Medical University
Li XY Xiaoyang, Master
the First Affiliated Hospital of Wenzhou Medical University
Interventions
  • Drug: Docetaxel — 75mg/m2 iv escalating to 100mg/m2 iv 3-weekly
  • Drug: Carboplatin — AUC=6 min/mL iv 3-weekly
  • Drug: Inetetamab — 8mg/kg iv loading dose, followed by 6mg/kg iv 3-weekly
  • Drug: Pyrotinib — 400mg orally daily
Study Locations (1 sites)
the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325000 China
Eligibility Criteria
Inclusion Criteria: 1. Female patients aged 18-75 years old; 2. ECOG score 0-1; 3. Breast cancer meets the following criteria: Histologically confirmed invasive breast cancer, primary tumor diameter \> 2 cm as determined by standard evaluation methods at the research center; tumor stage: locally advanced; 4. HER2 expression-positive breast cancer confirmed by pathological examination; 5. Known hormone receptor status (ER and PR); 6. The functional level of major organs must meet the following requirements (no blood transfusion within 2 weeks before screening, no use of white blood cell and platelet-raising drugs): (1) Blood routine: neutrophil (ANC) \>= 1.5×10\^9/L; platelet count (PLT) \>= 90×10\^9/L; hemoglobin (Hb) \>= 90 g/L; (2) Blood biochemistry: total bilirubin (TBIL) \<= upper limit of normal (ULN); alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \<= 1.5×ULN; alkaline phosphatase \<= 2.5×ULN; urea nitrogen (BUN) and creatinine (Cr) \<= 1.5×ULN; (3) Echocardiography: left ventricular ejection fraction (LVEF) \>= 60%; (4) 12-lead ECG: Fridericia-corrected QT interval (QTcF) \< 470 msec; 7. Female patients who are not menopausal or surgically sterilized: agree to abstain from sex or use effective contraceptive methods during treatment and for at least 7 months after the last dose in the study treatment; 8. Voluntarily join the study, sign the informed consent, have good compliance and are willing to cooperate with follow-up. Exclusion Criteria: 1. IV (metastatic) breast cancer; 2. Received anti-tumor therapy or radiotherapy for any malignant tumor in the past, excluding cured cervical carcinoma in situ, basal cell carcinoma or squamous cell carcinoma and other malignant tumors; 3. Receiving anti-tumor therapy in other clinical trials at the same time, including endocrine therapy, bisphosphonate therapy or immunotherapy; 4. Received major surgical operations unrelated to breast cancer within 4 weeks before enrollment, or the patient has not fully recovered from such surgical operations; 5. Severe cardiac disease or discomfort, including but not limited to the following: a history of heart failure or systolic dysfunction (LVEF \< 60%); high-risk uncontrolled arrhythmias, such as atrial tachycardia, resting heart rate \> 100 bpm , significant ventricular arrhythmia (eg, ventricular tachycardia) or higher-grade AV block (ie, Mobitz II second-degree AV block or third-degree AV block); antianginal medication indicated angina pectoris; clinically significant heart valve disease; transmural myocardial infarction on ECG; poorly controlled hypertension (systolic \> 180 mmHg and/or diastolic \> 100 mmHg); 6. Inability to swallow, intestinal obstruction, or other factors that affect drug taking and absorption; 7. Those who are known to have a history of allergy to the drug components of this regimen; have a history of immunodeficiency, including HIV positive test, or have other acquired or congenital immunodeficiency diseases, or have a history of organ transplantation; 8. Female patients during pregnancy and lactation, female patients with fertility and positive baseline pregnancy test, or patients of childbearing age who are unwilling to take effective contraceptive measures during the entire trial period and within 7 months after the last study drug; 9. Have serious comorbidities or other comorbidities that would interfere with planned treatment, or any other condition that the investigator considers the patient unsuitable to participate in this study.
Conditions Breast Atypical Hyperplasia, Breast Carc...
Phase PHASE2
Enrollment 80
Locations 4 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-30
Study Details Design, interventions, and primary outcomes

About This Study

This phase IIA trial compares the effect of acolbifene versus low dose tamoxifen in preventing breast cancer in premenopausal women at high risk for developing breast cancer. The usual approach for patients at increased risk for breast cancer is to undergo yearly breast magnetic resonance imaging or ultrasound in addition to yearly mammogram. Premenopausal women at very high lifetime risk for breast cancer (greater than 50%) can consider preventive removal (mastectomy) of both breasts. Premenopausal women age 35 or older with a prior diagnosis of atypical hyperplasia, lobular carcinoma in situ, or an estimated 10-year risk of greater than or equal to 3% or estimated 10-year risk of greater than or equal to 2-5 times that of the average woman (depending on age) may be advised to consider five years of standard dose tamoxifen. Standard dose tamoxifen is four times the dose used in this study. Estrogen can cause the development and growth of breast cancer cells. Acolbifene and tamoxifen blocks the use of estrogen by breast cells. This study may help researchers measure the effects of acolbifene and low dose tamoxifen on markers of breast cancer risk in mammogram imaging, breast tissue, and in blood samples.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: Double

Interventions / Regimen

  • Drug: Acolbifene Hydrochloride — Given PO
  • Procedure: Biospecimen Collection — Undergo collection of blood
  • Procedure: Mammography — Undergo 3D mammography
  • Other: Questionnaire Administration — Ancillary studies
  • Procedure: Random Periareolar Fine-Needle Aspiration — Undergo RPFNA
  • Drug: Tamoxifen — Given PO

Primary Outcomes

  • Change in the relative abundance of the specific sequence of messenger ribonucleic acid that codes for AGR2 (Baseline up to 6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2024-10-10
Completion: 2028-09-01
Eligibility
Age: 35 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 80 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: National Cancer Institute (NCI)
Principal Investigators:
  • Carol J Fabian (PRINCIPAL_INVESTIGATOR) - University of Kansas Medical Center
Contact Information
Study Contact:
Lisa D. Yee
626-218-7100
lyee@coh.org
City of Hope Comprehensive Cancer Center
Lisa D. Yee
City of Hope Comprehensive Cancer Center
Seema A. Khan
312-695-0990
skhan2@northwestern.edu
Northwestern University
Interventions
  • Drug: Acolbifene Hydrochloride — Given PO
  • Procedure: Biospecimen Collection — Undergo collection of blood
  • Procedure: Mammography — Undergo 3D mammography
  • Other: Questionnaire Administration — Ancillary studies
  • Procedure: Random Periareolar Fine-Needle Aspiration — Undergo RPFNA
Study Locations (4 sites)
City of Hope Comprehensive Cancer Center, Duarte, California 91010 United States
Northwestern University, Chicago, Illinois 60611 United States
University of Kansas Cancer Center, Kansas City, Kansas 66160 United States
Ohio State University Comprehensive Cancer Center, Columbus, Ohio 43210 United States
Eligibility Criteria
Inclusion Criteria: * Age \>= 35 years * Considered clinically premenopausal * Having regular menstrual cycles (between 21 and 35 days) unless a contraceptive device such as progestin containing intrauterine device (IUD) (e.g., Mirena IUD) or oral contraceptives is being used which suppresses menstrual periods, or premenopausal women who have undergone a hysterectomy, but have at least one intact ovary * Not considering pregnancy for at least 12 months * Women of child-bearing potential capacity who are heterosexually active must be willing to have used effective birth control precautions for 8 weeks prior to fine needle aspiration and be willing to continue for 8 weeks after study completion as tamoxifen may have teratogenic effects on the developing fetus. Reproductive and developmental toxicity studies have not been conducted with acolbifene. Should a woman become pregnant or suspect she is pregnant while participating in this study, she must stop study drug and inform her study physician immediately. * For women who are heterosexually active not using oral contraceptive (progestin alone or estrogen plus a progestin), two of the following are recommended but woman must agree to at least one of the following methods: * IUD non-hormonal or hormone containing (usually a progestin) intrauterine device (IUD) or rings. Any of these should have been inserted at least 8 weeks prior to RPFNA. * Barrier method (such as condoms and diaphragms or cervical caps with or without a spermicide) * Partner has had a vasectomy. * For women who are heterosexually active using oral contraceptive (progestin alone or estrogen plus a progestin), woman must agree to at least a non- hormonal IUD or a barrier method (below) or her partner must have had a vasectomy: * Non-hormonal IUD * Barrier method (such as condoms and diaphragms or cervical caps with or without a spermicide) * Partner has had a vasectomy * Must have increased breast cancer risk as predicted by any one or more of the conditions listed below or increased model calculated risk as below: * Any one or more of the following conditions associated with increased risk (condition must be documented in electronic medical record or copy of relevant pathology or genetic testing reports submitted with the eligibility checklist) * A prior biopsy at any time in the past showing ductal carcinoma in situ (DCIS), lobular carcinoma in situ (LCIS), atypical hyperplasia. (If DCIS must have been treated by mastectomy or local excision +/- radiation with this treatment completed at least 3 months prior to screening with RPFNA) * High or moderate penetrance risk pathogenic or likely pathogenic germline gene mutation in ATM, BARD1, BRIP1, CDH1, CHEK2, MSH6, NBN, NF1, PTEN, PMS2, RAD51C, RAD51D, TP53, BRCA2, or PALB2 * High polygenic risk score (Life-time risk of \>= 2x average or 25%) * Breast cancer in a first or second degree relative (female or male) with onset under age 50. First degree relative is defined as parent, sibling, or child. Second degree relative is defined as grandparent, uncle, aunt, nephew, niece, half-sibling, grandchild or first cousin * Two or more affected first or second-degree relatives from either the maternal or paternal lineage without regard to age * Bilateral breast cancer or breast and ovarian cancer in the same first or second degree relative without regard to age. * High mammographic density defined as either visual estimate of area of density (VAS) \> 50%, or Volpara (Trademark) \>= 15% dense volume (Volpara d) or Breast Imaging Reporting and Data System (BIRADS) assessment of extremely dense (BIRADs D) * Chest irradiation prior to age 30 * Alternatively, instead of conditions listed above, an increased risk of breast cancer as calculated by International Breast Cancer Intervention Study Version 8 (IBIS 8), or Breast Cancer Surveillance Consortium (BCSC) 3 by one or more of the following criteria: * 10-year risk of breast cancer of \>= 3% * Increase in age specific 10-year relative risk by age group * Age 35-39 10-year relative risk of \>= 5X that for age group * Age 40-44 10-year risk of \>= 4X that for age group * Age 45 and up 10-year risk of \>= 2X * IBIS Version 8 Remaining lifetime risk of \>= 25% or \>= 2X that of population * A copy of the output of model calculations from IBIS 8 (https://ems-trials.org/riskevaluator/), or BCSC version 3.0 (https://tools.bcsc-scc.org/BC5yearRisk/calculator.htm) online tools, if used for qualifying risk assessment, or polygenetic risk score should be submitted with the eligibility checklist. Otherwise, these risk qualifying factors need to be documented in the medical record if that is considered the source document * Women must have at least 1 unaffected untreated breast for fine needle aspiration. Women may have had prior unilateral breast radiation or mastectomy for DCIS * Eastern Cooperative Oncology Group (ECOG) current performance status (PS) ≤ 2 as documented within 3 months prior to randomization or Karnofsky score \>= 60% * Total bilirubin =\< 1.5 x institutional upper limit of normal (measured within 180 days prior to randomization) * Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \[SGOT\]) =\< 1.5 x institutional upper limit of normal (measured within 180 days prior to randomization) * Alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \[SGPT\]) =\< 1.5 x institutional upper limit of normal (measured within 180 days prior to randomization) * Creatinine =\< 2.0 mg/dL (measured within 180 days prior to randomization) * Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures * Ability to understand and the willingness to sign a written informed consent document * Confirmation that fixed (Cytolyt™) and frozen tissue specimens have been received in good condition at KUMC and are likely adequate for assessment of the primary endpoint. Confirmation will be provided by Protocol PI(s) and/or KUMC Laboratory personnel * Confirmation that a Volpara™ Score Card or a Volpara Data Manager (VDM)-generated Excel file has been received at KUMC and archived for assessment of the secondary endpoint. Confirmation will be provided by Protocol PI(s) and/or KUMC study coordinator. Alternatively, confirmation may be provided by site personnel that a raw image file in Digital Imaging and Communications in Medicine (DICOM) format has been archived at the site such that it can be later used for generation of a Volpara™ Score Card or Excel file Exclusion Criteria: * Bilateral breast implants (danger of implant puncture with RPFNA) * Women who are pregnant * Currently breastfeeding (concern that tamoxifen or acolbifene may be in breast milk) or nursing within the past 12 months (concern about milk fistula with RPFNA) * Prior invasive breast cancer within the past 5 years * Other prior invasive cancer \> T1 stage (other than non-melanoma skin) within the past 5 years * Pathogenic or likely pathogenic germline mutation in BRCA1 * Type I or Type II diabetes mellitus requiring treatment with prescription medication * Prior deep vein thrombosis, pulmonary embolus, or stroke * History of chronic liver disease including NASH (nonalcoholic steatohepatitis) and chronic hepatitis C * History of chronic hepatitis B or hepatitis C (danger of exacerbation of liver damage from hepatitis or tamoxifen-induced non-alcoholic fatty liver disease or non-alcoholic steatohepatitis) * History of human immunodeficiency virus (HIV)-infection (danger of exacerbation of underlying clinically inapparent liver damage caused by HIV and/or hepatotoxicity can be induced by interaction of tamoxifen-induced CYP3A4 with direct anti-hepatitis C virus \[HCV\] agents) * Current use of prescription anticoagulants such as Coumadin (warfarin), direct-acting oral anticoagulants such as Xarelto (rivaroxa
Conditions Breast Reconstruction, Perfusion; Compli...
Phase PHASE1
Enrollment 25
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-30
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of the study is to determine whether pharmacologic delay using minoxidil in patients undergoing bilateral risk reducing mastectomy with reconstruction could achieve improvement in flap perfusion and flap viability at the time of surgery. Patients will undergo randomization of their breasts to determine which breast will receive the experimental intervention and which breast will serve as the internal control (receive placebo). The experimental breast will receive the novel pharmacologic delay treatment, 5% minoxidil, while the internal control breast will receive the current standard of care, which does not include any topical application prior to surgery - a placebo control will be used. This will be a triple-blind study, where both the participants and investigators will be blinded to which breast will receive the intervention. The patients will receive two bottles "compound A" and "compound B" with directions from the pharmacy for which compound to apply to each breast. Product will be applied for 2 weeks prior to planned surgery. Surgery will proceed without any changes to standard practice.

Design

Study type: Interventional Phases: Phase1 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Drug: Minoxidil — Each participant will receive both topical agents in order to apply daily for 14-days prior to surgery.
  • Drug: Hair mousse — Each participant will receive both topical agents in order to apply daily for 14-days prior to surgery.

Primary Outcomes

  • Feasibility, as measured by recruitment rate (Day 1)
  • Feasibility, as measured by retention rate (90 days)
  • Feasibility, as measured by rate of participant adherence to the protocol (90 days)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2026-03-16
Completion: 2027-09
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 25 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Duke University
Principal Investigators:
  • Brett Phillips, MD (PRINCIPAL_INVESTIGATOR) - Duke University
Contact Information
Study Contact:
Jennifer Gallagher
9199701551
jennifer.gallagher@duke.edu
Jennifer Gallagher, BA
jennifer.gallagher@duke.edu
Duke Health
Interventions
  • Drug: Minoxidil — Each participant will receive both topical agents in order to apply daily for 14-days prior to surgery.
  • Drug: Hair mousse — Each participant will receive both topical agents in order to apply daily for 14-days prior to surgery.
Study Locations (1 sites)
Duke Health, Durham, North Carolina 27710 United States
Eligibility Criteria
Inclusion Criteria: 1. Female sex \> 18 years old 2. Genetic predisposition to cancer 3. Undergoing bilateral prophylactic mastectomy with same-day breast reconstruction 4. Capable of giving informed consent Exclusion Criteria: 1. Diagnosis of breast cancer 2. History of cancer 3. Currently pregnant or planning to be pregnant (for women of child-bearing potential) 4. Male sex
Conditions Metastatic Solid Tumor, Recurrent Solid ...
Phase PHASE1
Enrollment 420
Locations 39 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-30
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to find out whether the study drug, LY4052031, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors including urothelial cancer. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-expansion). The study will last up to approximately 4 years.

Design

Study type: Interventional Phases: Phase1 Allocation: Non Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: LY4052031 — Intravenous

Primary Outcomes

  • Phase 1a: To determine the recommended phase 2 dose (RP2D) optimal dose(s) of LY4052031 (Cycle 1 (21 Days))
  • Phase 1b: To assess the antitumor activity of LY4052031 Monotherapy: Overall response rate (ORR) (Up to Approximately 48 Months or 4 Years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2024-07-01
Completion: 2027-05
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 420 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Eli Lilly and Company
Principal Investigators:
  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST) (STUDY_DIRECTOR) - Eli Lilly and Company
Contact Information
Study Contact:
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
1-317-615-4559
LillyTrials@Lilly.com
Physicians interested in becoming principal investigators please contact
clinical_inquiry_hub@lilly.com
Interventions
  • Drug: LY4052031 — Intravenous
Study Locations (39 sites)
City of Hope National Medical Center, Duarte, California 91010-0269 United States
University of California, San Diego (UCSD) - Moores Cancer Center, La Jolla, California 92093 United States
UCLA Department of Medicine-Hematology/Oncology, Los Angeles, California 90024 United States
Sarah Cannon Research Institute at HealthOne, Denver, Colorado 80218 United States
Florida Cancer Specialists and Research Institute, St. Petersburg, Florida 33705 United States
University of Chicago Hospital, Chicago, Illinois 60637 United States
IU Simon Cancer Center, Indianapolis, Indiana 46202 United States
Massachusetts General Hospital, Boston, Massachusetts 02215 United States
START Midwest Cancer and Hematology Centers of W Michigan, Grand Rapids, Michigan 49546 United States
Washington University School of Medicine in St. Louis, St Louis, Missouri 63110 United States
Eligibility Criteria
Inclusion Criteria: * Have one of the following solid tumor cancers: * Cohort A1: urothelial carcinoma, triple negative breast cancer, non-small cell lung cancer, esophageal cancer, pancreatic cancer, ovarian cancer, cervical cancer (squamous cell carcinoma), head and neck squamous cell carcinoma or prostate cancer * Cohort A2/B1/B2: urothelial carcinoma * Cohort C: triple negative breast cancer, non-small cell lung cancer, ovarian cancer, cervical cancer, HNSCC (head and neck squamous cell carcinoma), esophageal cancer, pancreatic cancer, or prostate cancer * Prior Systemic Therapy Criteria: * Cohort A1/C: Individual has received all standard therapies for which the participant was deemed to be an appropriate candidate by the treating investigator; OR there is no standard therapy available for the disease. There is no restriction on number of prior therapies * Cohort A2/B1/B2: Individual must have received at least one prior regimen in the advanced or metastatic setting. There is no restriction on number of prior therapies. * Prior enfortumab vedotin specific requirements: * Cohorts A1/A2/C: prior treatment with enfortumab vedotin is allowed, but not required * Cohort B1: individual must be enfortumab vedotin naive in the advanced/metastatic setting * Cohort B2: individual must have received enfortumab vedotin in the metastatic/advanced setting. * Measurability of disease * Cohort A1: measurable or non-measurable disease as defined by Response Evaluation Criteria in Solid Tumors v1.1 (RECIST 1.1) * Measurable disease is required as defined by Response Evaluation Criteria in Solid Tumors v1.1 (RECIST v1.1) for all Cohorts. Cohort A1 may permit non-measurable disease as defined by RECIST v1.1 * Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * Have adequate archival tumor tissue sample available or undergo a screening biopsy if allowed per country specific regulations Exclusion Criteria: * Individual with known or suspected uncontrolled CNS metastases * Individual with uncontrolled hypercalcemia * Individual with uncontrolled diabetes * Individual with evidence of corneal keratopathy or keratitis, and history of corneal transplant * Any serious unresolved toxicities from prior therapy * Significant cardiovascular disease * Recent thromboembolic event and/or clinically significant bleeding disorder * Prolongation of QT interval corrected for heart rate using Fridericia's formula (QTcF) ≥ 470 ms * History of pneumonitis/interstitial lung disease * History of Grade ≥3 skin toxicity when receiving enfortumab vedotin * Individuals who are pregnant, breastfeeding or plan to breastfeed during study or within 30 days of last dose of study intervention
Conditions Breast, Breast Cancer, Pathology
Phase Not Applicable
Enrollment 2000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-30
Study Details Design, interventions, and primary outcomes

About This Study

Breast cancer is one of the most common malignancies in women worldwide, and distant metastasis is the main cause of poor prognosis and death. This project aims to construct a precision prediction system based on multi-omics (digital pathology, immunohistochemistry, proteomics, gene sequencing) and artificial intelligence to predict distant and organ-specific metastasis (bone, lung, liver, brain) in breast cancer, analyze its mechanisms, and provide new solutions for precision medicine.

Design

Study type: Observational Observational model: Cohort Time perspective: Retrospective

Primary Outcomes

  • Metastasis-Free Survival (From diagnosis up to December 30, 2028)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-12-01
Completion: 2028-12-30
Eligibility
Age: Not reported
Sex: FEMALE
Volunteers: false
Enrollment: 2000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Second Affiliated Hospital, Zhejiang University, School of Medicine
Contact Information
Study Contact:
Fengbo Huang, MD
0571-87783914
keyanlunli_zheer@163.com
Fengbo Huang, MD
0571-87783914
keyanlunli_zheer@163.com
The Second Affiliated Hospital, Zhejiang University School of Medicine
Jian Huang, MD, PhD
The Second Affiliated Hospital, Zhejiang University School of Medicine
Interventions
N/A
Study Locations (1 sites)
The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310000 China
Eligibility Criteria
Inclusion Criteria: 1. Female patients pathologically diagnosed with breast cancer at our hospital or participating centers between January 1, 2000, and December 30, 2028. 2. Must meet one of the following: 1) Initially diagnosed with breast cancer at our hospital, has developed distant metastasis (liver, bone, lung, or brain), and has a biopsy or surgical specimen from the metastatic site stored at our hospital, with complete clinical information available. 2) Primary tumor specimen is not at our hospital, but a biopsy or surgical specimen from a distant metastatic site (liver, bone, lung, brain) is stored at our hospital. Exclusion Criteria: 1. Concomitant metastatic malignancy from another primary cancer. 2. Incomplete clinical information.